ResultsIQ

ResultsIQ › Latest results › Epigral Limited

Epigral Limited Q2 FY27 earnings call summary

NSE: EPIGRAL · BSE: 543332

Earnings call of 2 Nov 2026, summarised by AI from the filing.

Epigral's Q2 FY27 revenue rose 28% to ₹752 cr but EBITDA margin was 18% on high raw material costs; CPVC and ECH plants to be commissioned within a quarter.

Key takeaways

  1. FY31 target Revenue of ₹5,000-5,100 cr by FY31 estimated on current realizations and gradual utilization ramp-up.
  2. Commissioning CPVC and Epichlorohydrin expansions in final stages with trial runs underway, to be commissioned within a quarter.
  3. Derivatives mix Derivatives and specialty business contributed 57% of Q2 FY27 revenue, with the transition to accelerate on new capex.

Original filing on BSE

Epigral Limited Q2 FY27 results

As filed: Revenue ₹746 cr (+27% year on year), EBITDA ₹136 cr (+3% year on year), PAT ₹65.1 cr (+28% year on year), EBITDA margin 18.3% (−424 bps).

The Q2 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q1 FY27: Revenue ₹705 cr (+16% year on year), EBITDA ₹179 cr (+9% year on year), PAT ₹99.7 cr (−38% year on year), EBITDA margin 25.4% (−161 bps). Score 47 of 100, In line with trend. Revenue and EBITDA growth were in line with the company's own trend; profit growth was below it. EBITDA margin fell 161 bps year on year. Revenue fell 4% from last quarter. Share price after the results: +7.4% in 30 days (Nifty 500: +2.8%).
  • Q4 FY26: Revenue ₹736 cr (+17% year on year), EBITDA ₹169 cr (−3% year on year), PAT ₹81.0 cr (−7% year on year), EBITDA margin 22.9% (−481 bps). Score 55 of 100, In line with trend. Revenue and EBITDA growth were in line with the company's own trend; profit growth was below it. EBITDA margin fell 481 bps year on year. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: −4.8% in 30 days (Nifty 500: −1.1%).
  • Q3 FY26: Revenue ₹597 cr (−7% year on year), EBITDA ₹103 cr (−44% year on year), PAT ₹39.1 cr (−62% year on year), EBITDA margin 17.2% (−1,000 bps). Score 18 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 1000 bps year on year. Profit fell 23% from last quarter. Share price after the results: −6.3% in 28 days (Nifty 500: +0.1%).
  • Q2 FY26: Revenue ₹587 cr (−6% year on year), EBITDA ₹132 cr (−25% year on year), PAT ₹51.0 cr (−37% year on year), EBITDA margin 22.5% (−579 bps). Score 14 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 579 bps year on year. Revenue fell 3% from last quarter. Share price after the results: −13.2% in 30 days (Nifty 500: −0.5%).
  • Q1 FY26: Revenue ₹607 cr (−7% year on year), EBITDA ₹164 cr (−7% year on year), PAT ₹161 cr (+87% year on year), EBITDA margin 27.0% (−2 bps). Score 41 of 100, In line with trend. EBITDA margin was flat year on year. Tax rate -50%. Not enough history for a trend yet: scored on growth alone. Revenue fell 3% from last quarter. Share price after the results: −7.9% in 30 days (Nifty 500: +0.8%).
  • Q4 FY25: Revenue ₹628 cr (+20% year on year), EBITDA ₹174 cr (+12% year on year), PAT ₹87.0 cr (+13% year on year), EBITDA margin 27.7% (−182 bps). Score 53 of 100, In line with trend. EBITDA margin fell 182 bps year on year. Not enough history for a trend yet: scored on growth alone. Profit fell 16% from last quarter. Share price after the results: +0.7% in 30 days (Nifty 500: +3.6%).
  • Q3 FY25: Revenue ₹645 cr (+37% year on year), EBITDA ₹183 cr (+49% year on year), PAT ₹104 cr (+112% year on year), EBITDA margin 28.4% (+231 bps). Score 92 of 100, Above trend. EBITDA margin rose 231 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Epigral Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.